These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31114348)

  • 1. Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis.
    Wang K; Ren Y; Ma Z; Li F; Cheng X; Xiao J; Zhang S; Yu Z; Yang H; Zhou H; Li Y; Liu H; Jiao ZY
    Cancer Manag Res; 2019; 11():3009-3020. PubMed ID: 31114348
    [No Abstract]   [Full Text] [Related]  

  • 2. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
    Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
    Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    Lorenzen S; Pauligk C; Homann N; Schmalenberg H; Jäger E; Al-Batran SE
    Br J Cancer; 2013 Feb; 108(3):519-26. PubMed ID: 23322206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative Safety and Effectiveness of Neoadjuvant Therapy with Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel Plus Apatinib in Locally Advanced Gastric Cancer.
    Zhang Y; Zhang B; Yang J; Zhang J; Zhang W
    Cancer Manag Res; 2021; 13():2279-2286. PubMed ID: 33732020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    Dos Santos M; Lequesne J; Leconte A; Corbinais S; Parzy A; Guilloit JM; Varatharajah S; Brachet PE; Dorbeau M; Vaur D; Weiswald LB; Poulain L; Le Gallic C; Castera-Tellier M; Galais MP; Clarisse B
    BMC Cancer; 2022 May; 22(1):537. PubMed ID: 35549674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Sisic L; Crnovrsanin N; Nienhueser H; Jung JO; Schiefer S; Haag GM; Bruckner T; Schneider M; Müller-Stich BP; Büchler MW; Schmidt T
    Langenbecks Arch Surg; 2023 Feb; 408(1):81. PubMed ID: 36763220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer.
    Sah BK; Zhang B; Zhang H; Li J; Yuan F; Ma T; Shi M; Xu W; Zhu Z; Liu W; Yan C; Li C; Liu B; Yan M; Zhu Z
    Nat Commun; 2020 Nov; 11(1):6093. PubMed ID: 33257672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience.
    Tastekin D; Paksoy N; Dogan I; Ferhatoglu F; Khanmammadov N; Bozbey HU; Karabulut S
    J Cancer Res Ther; 2023; 19(2):253-258. PubMed ID: 37006064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
    Möhring C; Timotheou A; Mańczak A; Sadeghlar F; Zhou T; Mahn R; Bartels A; Monin M; Toma M; Feldmann G; Brossart P; Köksal M; Sarria GR; Giordano FA; Lingohr P; Jafari A; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
    J Cancer Res Clin Oncol; 2023 May; 149(5):1849-1862. PubMed ID: 35763109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The New Era of Total Neoadjuvant FLOT Therapy for Locally Advanced, Resectable Gastric Cancer: A Propensity-Matched Comparison With Standard Perioperative Therapy.
    Rencuzogullari A; Karahan SN; Selcukbiricik F; Lacin S; Taskin OC; Saka B; Karahacioglu D; Gurses B; Ozoran E; Uymaz DS; Ozata IH; Saglam S; Bugra D; Balik E
    J Surg Oncol; 2024 Oct; ():. PubMed ID: 39400342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety.
    Villanueva L; Anabalon J; Butte JM; Salman P; Panay S; Milla E; Gallardo C; Hoefler S; Charles R; Reyes F; Barajas O; Matamala L; Molina A; Portiño S; Berrios M; Caglevic C; Mahave M
    Ecancermedicalscience; 2021; 15():1168. PubMed ID: 33680082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    Moussa O; Bhogal RH; Malietzis G; Fribbens C; Starling N; Gerlinger M; Watkins D; Chau I; Rao S; Cunningham D; Allum WH; Chaudry A; Kumar S
    BJS Open; 2022 Jan; 6(1):. PubMed ID: 35195263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-finding study of modified FLOT (mFLOT) regimen as first-line treatment in Chinese patients with metastatic adenocarcinoma of stomach.
    Zhou C; Ma T; Shi M; Xi W; Wu J; Yang C; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):113-119. PubMed ID: 31691079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of FLOT regimen
    Farrokhi P; Sadeghi A; Sharifi M; Riechelmann R; Moghaddas A
    Res Pharm Sci; 2022 Dec; 17(6):621-634. PubMed ID: 36704436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China.
    Sah BK; Xu W; Zhang B; Zhang H; Yuan F; Li J; Liu W; Yan C; Li C; Yan M; Zhu Z
    Front Oncol; 2020; 10():567529. PubMed ID: 33537232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study.
    Forouhari A; Moghaddas A; Darakhshandeh A
    J Res Med Sci; 2023; 28():79. PubMed ID: 38292337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Does the FLOT regimen a new standard of perioperative chemotherapy for localized gastric cancer?].
    Adenis A; Samalin E; Mazard T; Portales F; Mourregot A; Ychou M
    Bull Cancer; 2020 Jan; 107(1):54-60. PubMed ID: 31980145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Significance of Ki-67 and Platelet Lymphocyte Ratio in Patients with Gastric Cancer Receiving Neoadjuvant FLOT Chemotherapy.
    Yilmaz H; Demirag G; Sullu Y; Yilmaz A
    J Coll Physicians Surg Pak; 2021 May; 31(5):546-552. PubMed ID: 34027867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.